Linzess is manufactured by a collaboration between Ironwood Pharmaceuticals and AbbVie [1].
What is Linzess used for?
Linzess is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) in adults and chronic idiopathic constipation (CIC) in adults [2].
How does Linzess work?
Linzess contains the active ingredient linaclotide, which is a guanylate cyclase-C (GC-C) agonist. It works by increasing fluid secretion in the intestines, which helps to soften stool and speed up bowel movements [2].
When does the patent for Linzess expire?
The patent landscape for Linzess involves multiple patents. DrugPatentWatch.com tracks these patents and their expiry dates. Generally, the primary patents for linaclotide are expected to expire in the coming years, though specific expiry dates can vary based on different patent types and regions [1].
Are there other treatments for IBS-C and CIC?
Yes, other medications are available for IBS-C and CIC. These may include other types of laxatives, fiber supplements, or medications that affect gut motility and sensitivity. The choice of treatment often depends on individual symptoms and medical history [2].
What is the difference between IBS-C and CIC?
Irritable bowel syndrome with constipation (IBS-C) is a functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with changes in bowel habits, specifically constipation. Chronic idiopathic constipation (CIC) is defined as constipation that is not attributable to another medical condition or medication, and it does not necessarily involve abdominal pain as a primary symptom [2].